SCHEMBL20477366

SCHEMBL20477366

CCOC(=O)c1nn(Cc2c(F)cccc2F)cc1CC=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
KDM4E B2RXH2 4/20 0.43
NPC1 O15118 6/20 0.41
RAB9A P51151 4/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CA5A P35218 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
ALOX15 P16050 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ELANE P08246 2/20 0.37
EED O75530 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPT P10636 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20477406 0.89 KMT2A (0.47) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL20477243 0.83 ALDH1A1 (0.53) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL20477442 0.81 NPC1 (0.47) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL24709863 0.79 ALDH1A1 (0.42) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL28529845 0.78 ALDH1A1 (0.41) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL28529843 0.78 ALDH1A1 (0.41) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL20477416 0.77 ALDH1A1 (0.42) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL20477381 0.74 KMT2A (0.51) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL28831808 0.74 L3MBTL1 (0.46) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL28235169 0.73 CA5A (0.39) ALDH1A1MEN1KMT2ACA5ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108431004-B Heterocyclic compounds 武田药品工业株式会社 2021-02-12 CN disclosed
US-10787462-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-09-29 US disclosed
EP-3366684-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2020-09-02 EP disclosed
US-20180319819-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-11-08 US disclosed
EP-3366684-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787462-B2 Heterocyclic compound RIPK1, RIPK4, RIPK3 ALDH1A1 2773/4885KDM4E 2413/4885NPC1 44/4885
US-20180319819-A1 HETEROCYCLIC COMPOUND RIPK1, RIPK4, RIPK3 ALDH1A1 2773/4885KDM4E 2413/4885NPC1 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.